Please ensure Javascript is enabled for purposes of website accessibility

Idexx Laboratories Tops Q1 Estimates Despite COVID-19 Impact

By Keith Speights – Apr 30, 2020 at 12:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company withdrew its full-year guidance because of the COVID-19 pandemic but is seeing some signs of improvement in April.

Business boomed for Idexx Laboratories (IDXX 3.34%) in 2019. But there were plenty of questions for the animal health company in the first quarter of 2020 due to the COVID-19 pandemic. Those questions have now been answered.

Idexx Labs announced its first-quarter results before the market opened on Thursday. The company's business is still booming. Here are the highlights from Idexx's Q1 update.


Image source: Getty Images.

By the numbers

Idexx reported first-quarter revenue of $626 million, a 9% year-over-year jump. This result also handily beat the average analysts' revenue estimate of $617.4 million.

The company announced Q1 net income of $111.9 million, or $1.29 per share, based on generally accepted accounting principles (GAAP). Idexx's bottom line improved from the prior-year period, when the company recorded GAAP earnings of $102.7 million, or $1.17 per share. The animal health company's Q1 earnings also topped the consensus analysts' earnings estimate of $1.20 per share.

Idexx ended the first quarter with cash, cash equivalents, and short-term investments of $81.4 million, down from a cash stockpile of $90.3 million as of March 31, 2019.

Behind the numbers

COVID-19 both helped and hurt Idexx Labs in the first quarter. On the positive side, the company's livestock, poultry, and dairy (LPD) business benefited from accelerated customer stock orders due to the pandemic. LPD revenue jumped 12% higher than the total in the prior-year period.

It was a similar story for Idexx's water microbiology testing business. Revenue for the unit rose 13% year over year thanks in large part to customers stocking up because of the COVID-19 outbreak.

But Idexx's companion animal group, which generates 88% of the company's total revenue, was negatively impacted by the coronavirus. The business reported 8% year-over-year revenue growth, led by diagnostics recurring revenue growth of 10%.

However, companion animal group revenue began to slide in the latter part of the first quarter. Even though most states recognized veterinary care as an essential business, veterinary visits fell as customers stayed home and delayed elective procedures and wellness visits for their pets.

Looking ahead

The next few months hold a lot of uncertainty for many healthcare stocks. Idexx Labs is no exception. The company withdrew its previous full-year 2020 guidance due to a lack of visibility on how the COVID-19 pandemic could impact its business. However, there are reasons to be optimistic.

Idexx remains strong financially. The company increased its financial flexibility in Q1 by increasing its credit facility to $1 billion and issuing $200 million in notes. It also reduced spending by around $25 million compared to its planned levels through temporary pay cuts for executives and most salaried employees and suspending cash compensation for board members.

New COVID-19 diagnostic products could also boost sales. Idexx launched a new COVID-19 test for pets in April in response to both customer demand and increased evidence that pets can be infected by the novel virus that causes COVID-19. The company also awaits FDA emergency use authorization for a human COVID-19 test developed by its human health business, OPTI Medical Systems.

Perhaps most importantly, Idexx stated that it has seen "meaningful improvements" in its tracking of clinical visit and diagnostic testing trends in mid- to late April. The company said that areas that have begun to allow businesses to reopen and moderate social distancing requirements appear to be driving these improvements.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Idexx Laboratories. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

IDEXX Laboratories, Inc. Stock Quote
IDEXX Laboratories, Inc.
$336.68 (3.34%) $10.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.